Temporal changes in mortality and risk factors of candidemia in intensive care unit patients
Open Access
- 6 June 2026
- journal article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Abstract
Background: Candida species are major causes of hospital-acquired bloodstream infections associated with high mortality in critically ill patients. This study aimed to evaluate temporal changes in species distribution, antifungal resistance, clinical outcomes, and mortality predictors in ICU patients with candidemia. Methods: This retrospective study included 250 ICU patients with candidemia between January 2018 and January 2022. The study period was divided into two cohorts (2018–2020, n = 80; 2020–2022, n = 170). Clinical, laboratory, and microbiological characteristics were compared. Multivariable analysis was performed to identify independent predictors of mortality. Results: The incidence density of candidemia significantly decreased from 4.32 to 3.10 per 1,000 ICU patient-days (IRR: 0.72; %95 CI: 0.55–0.94; p = 0,014). A shift toward non-albicans Candida species was observed, while antifungal resistance rates remained stable. Candida score values and empirical antifungal therapy rates were lower in the later period. Despite increased central venous catheter use, catheter-related candidemia decreased. Overall mortality was similar between periods; however, during the second period, mortality was higher in patients with SARS-CoV-2 infection than in those without infection [100/105 (95.2%) vs. 43/65 (66.2%), p < 0.001]. In multivariable analysis, SOFA score was independently associated with mortality in the early period (OR: 1.20, 95% CI: 1.01–1.43; p = 0.043), whereas SARS-CoV-2 infection (OR: 20.43, 95% CI: 3.53–118.14; p = 0.001), Candida score (OR: 0.19, 95% CI: 0.06–0.50; p = 0.003), lactate level at ICU admission (OR: 5.23, 95% CI: 1.55–17.57; p = 0.007), and urea level at ICU admission (OR: 1.01, 95% CI: 1.00–1.02; p = 0.030) were independent predictors in the later period. Conclusion: The high mortality observed among patients with SARS-CoV-2–associated candidemia underscores the need for heightened diagnostic awareness in deteriorating ICU patients. Early diagnostic work-up, timely initiation of antifungal therapy, and reassessment of treatment according to microbiological findings are important in this setting. Hospital-specific identification of preventable risk factors may also help optimize candidemia management and infection control strategies.Keywords
This publication has 39 references indexed in Scilit:
- Risk factors associated with short-term mortality in patients with candidemia and the predictive value of serum cytokine levelCytokine, 2024
- Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort StudyJournal of Infection, 2024
- Risk factors for healthcare-associated candidemia in adults hospitalized with SARS-CoV-2 infectionAntimicrobial Stewardship & Healthcare Epidemiology, 2024
- Role of source control in critically ill candidemic patients: a multicenter retrospective studyInfection, 2024
- Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemicThe Brazilian Journal of Infectious Diseases, 2022
- Risk Factors for Invasive Candida Infection in Critically Ill PatientsChest, 2021
- ICU-acquired bloodstream infections in critically ill patients with COVID-19Journal of Hospital Infection, 2021
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysisClinical Microbiology and Infection, 2019
- Epidemiology of nosocomial candidaemia in a university hospital: a 12-year studyEpidemiology and Infection, 2010